Key facts
- Stellular Bio’s last known valuation is $166.0M (Oct 2021).
- It has raised $93.8M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Qiming Venture Partners USA, Cockrell Interests, EQx Fund, Ziff Capital Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Stellular Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Stellular Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stellular Bio
Developer of a pioneering platelet-derived regenerative biologic platform designed to improve the lives of patients with ocular surface disease. The company's programmable logic controller platform is focused on harnessing and modifying the regenerative power of platelets and has regenerative potential that underlies autologous treatments like platelet-rich plasma but in the form of a mass-manufactured treatment that is standardized, off-the-shelf, and low enough cost to be able to reach all OSD patients, enabling researchers to create reengineering cell therapies that are well-characterized, reproducible and tunable.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2013
- Employees
- 10
- Website
- stellularbio.com/
- Ownership
- Privately Held (backing)
Stellular Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stellular Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stellular Bio in its N-PORT filings yet. We sweep new filings monthly.